Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Debiopharm International SA
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to provide written informed consent and to comply with study procedures.
Diagnosis of bone or joint infection which fulfils the following conditions: a) Infection is due to S. aureus (MSSA or MRSA) and/or CoNS only; and, b) Participants had received no more than 7 days of empiric antibiotics prior to initiating treatment with study drug unless the pathogen isolated was resistant to the administered empiric antibiotics; and, c) Biofilm is not considered to be yet established and/or has been mechanically eradicated; and, d) Infection is not associated with an ischiatic or a sacral osteomyelitis; and e) Infection can involve periosteal or soft tissue.
You may not be if
Presence of co-infection with non-staphylococcal bacteria at the affected joint or bone site, or in the blood.
Participants at an increased risk of developing liver injury.
Participants who have medical conditions that increase the risk of QT prolongation.
Medical history within the previous 3 months of: myocardial infarction, unstable angina pectoris, coronary artery or cerebral revascularization procedure or stroke, ventricular tachycardia, multifocal ventricular ectopics requiring treatment, or any other clinically relevant symptomatic ventricular arrhythmias.
Documented history of alcohol or drug abuse within the previous 12 months.
For patients with DFO:
1. Severe peripheral arterial disease (PAD) requiring revascularization; however, patients with peripheral artery disease are eligible for inclusion, provided they have undergone successful revascularization or it has been deemed unnecessary by a vascular surgeon
2. Necrotizing fasciitis or gangrene requiring complete lower extremity amputation (of all infected bone and soft tissue).
3. Patients with Charcot foot (suspected neuro-osteoarthropathy according to Investigator's judgment).
